Dr. David Shulkin’s New Role at Orpyx Medical Technologies
In a significant development for veteran healthcare and diabetes prevention, Orpyx® Medical Technologies Inc. has announced that Dr. David Shulkin, who served as the Ninth Secretary of the U.S. Department of Veterans Affairs (VA), will be joining its advisory board. This strategic appointment is expected to leverage Dr. Shulkin’s extensive experience in health policy and operational innovation, particularly within the VA and broader healthcare systems across the United States. Dr. Shulkin’s involvement is seen as a pivotal move to enhance the preventive measures for diabetic complications that disproportionately affect veterans.
Addressing the Diabetes Challenge Among Veterans
The Department of Veterans Affairs operates one of the largest integrated health systems globally, uniquely positioned to tackle critical health issues faced by veterans. The VA’s Prevention of Amputations In Veterans Everywhere (PAVE) program exemplifies this commitment, focusing on preventing diabetic foot ulcers (DFUs) and subsequent amputations. Recent data from the Veteran Health Administration (VHA) indicates that over 1.6 million veterans with diabetes are receiving care, with more than 49,000 cases of diabetic foot ulcers treated in the last fiscal year alone. Alarmingly, 15% of those who develop these ulcers may face amputation, highlighting the urgent need for effective preventive strategies.
Dr. Shulkin emphasized the dual significance of addressing diabetic foot ulcers, noting that it is both a medical necessity and an economic concern. He suggested that the innovative technology offered by Orpyx aligns well with the VA’s mission to improve health outcomes for veterans while reducing substantial healthcare costs associated with diabetes-related complications, which can amount to approximately $50,000 in savings for each prevented amputation.
Strategic Insights from a Healthcare Leader
Breanne Everett, CEO and founder of Orpyx, acknowledged Dr. Shulkin’s reputation as a leader in healthcare policy, particularly in the realms of value-based care and chronic disease prevention. She expressed confidence that his strategic insights will facilitate rapid expansion of Orpyx’s technologies across the VA and other major healthcare networks. The aim is to confront the challenges posed by diabetes-related foot complications, which currently contribute to over $80 billion in annual healthcare expenditures in the United States.
Dr. Shulkin’s addition to Orpyx’s advisory board not only enhances the company’s leadership in digital health but also strengthens its capacity to implement preventive care solutions on a national scale. Orpyx is dedicated to assisting individuals with diabetes in maintaining their independence through its patented sensor-enabled smart insole system and integrated remote care program, which are designed to detect early warning signs and prompt timely medical intervention.
About Orpyx Medical Technologies Inc.
Orpyx is recognized for its commitment to improving the quality of life for those living with diabetes. By partnering with VA Medical Centers, health systems, and payers throughout North America, Orpyx aims to deliver clinically validated outcomes that not only enhance patient care but also realize cost savings on a large scale. The company’s innovative approach is set to play a crucial role in transforming how diabetes-related health issues among veterans are managed in the future.
Related
